Zhanglin Lin Cui

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Venues

Journal of comparative effectiveness research

Future oncology (London, England)

JMIR cancer

Current medical research and opinion

Eli Lilly and Company

North Carolina State University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Eli Lilly and Company May 06 2002

United States

Principal Research Scientist :: Statistics

Education History

North Carolina State University Sep 01 1995 - May 31 1999

United States

PHD

Publications

Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Kristin M Sheffield, Jessica R Peachey, Michael Method, Brenda R Grimes, Jacqueline Brown, Kim Saverno, Tomoko Sugihara, Zhanglin Lin Cui, Kimberley T Lee
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future oncology (London, England) 18 (21) (2022)
Katherine B Winfree, Kristin M Sheffield, Zhanglin Lin Cui, Tomoko Sugihara, Josephine Feliciano
Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer. Current medical research and opinion (2021)
Zhanglin Lin Cui, Zbigniew Kadziola, Ilya Lipkovich, Douglas E Faries, Kristin M Sheffield, Gebra Cuyun Carter
Predicting optimal treatment regimens for patients with HR+/HER2- breast cancer using machine learning based on electronic health records. Journal of comparative effectiveness research 10 (9) (2021)
Michael Grabner, Cliff Molife, Liya Wang, Katherine B Winfree, Zhanglin Lin Cui, Gebra Cuyun Carter, Lisa M Hess
Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration. JMIR cancer 7 (2) (2021)
Lisa M Hess, Michael Grabner, Liya Wang, Astra M Liepa, Xiaohong Ivy Li, Zhanglin Lin Cui, Lee Bowman, William R Schelman
Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States. Pragmatic and observational research 11 (2020)

Zhanglin Lin Cui.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Zhanglin Lin Cui